Next to antibodies, several CD70-targeting chimeric antigen receptor (CAR) T-cell therapies have more recently entered the clinical (trial) arena showing great success in hematological malignancies, and are currently enrolling patients with advanced/metastatic renal cell carcinoma (NCT04438083, NCT04696731), T-cell lymphoma (NCT04502446), AML, multiple myeloma and non-Hodgkin lymphoma (NCT04662294) (Starzer and Berghoff 2020). Here, CD70 is linked to acute myeloid leukemia.